Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulationsBusiness Overview: Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers,...
Vista Pharma's Board approved Q1 results, showing a net loss of Rs. 0.99 Cr with Nil revenue. Facing significant 'going concern' doubts due to NPA and negative working capital, the company expects Rs. 9.22 Cr from warrant subscribers to support operations.
Vista Pharmaceuticals Limited announced it has completed its share dematerialization process for the quarter ended June 30, 2026. The company certified that all securities received for dematerialization were properly verified, mutilated, and cancelled. Crucially, the depository's name was updated as the registered owner in company records in a timely manner....
Vista Pharmaceuticals has closed its trading window, effective July 1st. This measure restricts designated individuals and their immediate relatives from trading company shares. The window will reopen 48 hours after the financial results for the quarter ending June 30, 2026, are announced. This is a standard step to ensure fair...
Vista Pharmaceuticals has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by a Practicing Company Secretary, confirms the company's compliance with applicable regulatory provisions and guidelines during the review period. This update signifies sound corporate governance, with no reported deviations from...
